Treatment success Fair, good or excellent effectiveness · Adults with lateral elbow pain
Oral NSAIDs showed no clear difference in treatment success Fair, good or excellent effectiveness compared with placebo (low certainty).
1 finding from 1 review
Quality of life · Adults with lateral elbow pain
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
ASAS 40 · Patients with AS
The review found no eligible studies for this question.
1 finding from 1 review
Partial remission ( · Patients with AS
The review found no eligible studies for this question.
1 finding from 1 review
BASFI (score from 0 to 10, 0=excellent, 10=poor function) · Patients with AS
1 finding from 1 review
X‐Ray of the spine · Patients with AS
The review found no eligible studies for this question.
1 finding from 1 review
MRI · Patients with AS
The review found no eligible studies for this question.
1 finding from 1 review
Serious adverse event · Patients with AS
The review found no eligible studies for this question.
1 finding from 1 review
Withdrawals due to any reason · Patients with AS
MTX treated showed no clear difference in withdrawal for any reason compared with no MTX treated (low certainty).
1 finding from 1 review
Intervention not reported
ACR50 American College of Rheumatology 50% improvement criteria · participants with rheumatoid arthritis and with a partial response to DMARDs
The intervention probably leads to higher ACR50 American College of Rheumatology 50% improvement criteria (moderate certainty).
1 finding from 1 review
Intervention not reported
Reduction in disability score Health Assessment Questionnaire (mean improvement from baseline). Scale from: 0 to 3 · participants with rheumatoid arthritis and with partial response to MTX
1 finding from 1 review
Intervention not reported
Radiographic progression Total Sharp Score · participants with rheumatoid arthritis and with partial response to MTX
1 finding from 1 review
Intervention not reported
Withdrawals due to adverse events · participants with rheumatoid arthritis and with partial response to MTX
The intervention showed no clear difference in withdrawals due to adverse events (moderate certainty).
1 finding from 1 review
Intervention not reported
Serious adverse events · participants with rheumatoid arthritis and with partial response to MTX
The intervention showed no clear difference in serious adverse events (moderate certainty).
1 finding from 1 review
Intervention not reported
Serious infections · participants with rheumatoid arthritis and with partial response to MTX
1 finding from 1 review
Intervention not reported
Etanercept (25 mg) + DMARD · participants with rheumatoid arthritis
The intervention leads to higher etanercept (25 mg) + DMARD (high certainty).
1 finding from 1 review
Intervention not reported
Etanercept (10 mg) · participants with rheumatoid arthritis
The intervention leads to lower etanercept (10 mg) (high certainty).
1 finding from 1 review
Intervention not reported
Etanercept (25 mg) · participants with rheumatoid arthritis
The intervention leads to higher etanercept (25 mg) (high certainty).
1 finding from 1 review
Intervention not reported
Serious infections · participants with rheumatoid arthritis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Intervention not reported
Outcome: ACR50 ‐ American College of Rheumatology Improvement Criteria · participants with rheumatoid arthritis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found